Nuvectis Pharma, Inc. (NVCT)
$9.41
+1.43 (+17.92%)
Rating:
Recommendation:
-
| Symbol | NVCT |
|---|---|
| Price | $9.41 |
| Beta | 0.000 |
| Volume Avg. | 0.04M |
| Market Cap | 137.786M |
| Shares () | - |
| 52 Week Range | 3.08-20.92 |
| 1y Target Est | - |
| DCF Unlevered | NVCT DCF -> | |
|---|---|---|
| DCF Levered | NVCT LDCF -> | |
| ROE | -232.73% | Strong Sell |
| ROA | -82.89% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 22.05% | Neutral |
| P/E | - | |
| P/B | 6.49 | Strong Buy |
Latest NVCT news
About
Download (Excel)Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.